1 unknown. 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 1 | Unknown 1 |
Follow Xiang Lu: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Neoadjuvant Tislelizumab Plus Chemotherapy for Resectable Locally-advanced Head and Neck Squamous Cell Carcinoma Tislelizumab, Nab-paclitaxel, Carboplatin - Head and Neck Squamous Cell Carcinomas, Resectable Head and Neck Squamous-cell Carcinoma | Phase 2 | Unknown | Xiang Lu | 30 | 2023-01-01 | 2024-02-01 |
Squamous Cell Carcinoma of Head and Neck (1)
130-nm albumin-bound paclitaxel (1) · Carboplatin (1) · tislelizumab (1)
China (1)